



Congrés Català
d'Obstetrícia i Ginecologia

7, 8 i 9 de novembre de 2018

Auditori AXA
BARCELONA

Dr. Xavier Bonfill

Director

Centre Cochrane Iberoamericà

Institut per l'Excel·lència Clínica i Sanitària

Servei d' Epidemiologia Clínica i Salut Pública

Hospital de la Santa Creu i Sant Pau

Universitat Autònoma de Barcelona.

Cullera de fusta per l'Obstetrícia

- Archie Cochrane (1979): “for the worst use of randomised clinical trials”




Figure 5

Last wooden spoon awarded at St. Johns College, Cambridge University, 1909. A British booby prize, it was given annually to the student with the lowest score on the comprehensive mathematics exam at Cambridge University -- implying that the student was better equipped to be a cook than a scholar.



Cullera de fusta per l'Obstetrícia ?

e 2).

"Really?"

Yes...
desPLEX
 to prevent ABORTION, MISCARRIAGE and
 PREMATURE LABOR

*recommended for routine prophylaxis
 in ALL pregnancies . . .*

96 per cent live delivery with desPLEX
 in one series of 1200 patients*—
 — bigger and stronger babies, too.†




No gastric or other side effects with desPLEX
 — in either high or low dosage.***

(Each desPLEX tablet starts with 25 mg. of diethylstilbestrol, U.S.P., which is then ultramicronized to smooth and accelerate absorption and activity. A portion of this ultramicronized diethylstilbestrol is even included in the tablet coating to assure prompt help in emergencies. desPLEX tablets also contain vitamin C and certain members of the vitamin B complex to aid detoxification in pregnancy and the effectuation of estrogen.)




For further data and a generous
 trial supply of desPLEX, write to:
 Medical Director

REFERENCES: 1. Condon, E. W., et al., *Am. J. Obst. & Gynec.* 63:1708, 1952.
 2. Condon, E. W., and Page, R. A., *Am. J. Obst. & Gynec.* 60:1213, 1950.
 3. Condon, E. W., and Page, R. A., *Am. J. Obst. & Gynec.* 61:1152, 1951.
 4. Fink, S. D., *Am. J. Obst. & Gynec.* 1954, *Am. J. Surg.* 87:91, 1954.
 5. Ross, J. W., *J. Obst. & Gynec.* 41: 413, 1951, 42: 224, 1952.


GRANT CHEMICAL COMPANY, INC., Brooklyn 26, N.Y.



Pràctiques efectives en Obstetrícia



Pràctiques efectives en Obstetrícia



La Col·laboració Cochrane

Cochrane és una xarxa global i independent de professionals de la salut, investigadors, representants de ciutadans i pacients, entre d'altres, creada per respondre a l'enorme repte de convertir les grans quantitats d'informació generades per la investigació clínica en coneixement útil per prendre decisions.

Impulsem aquest objectiu mitjançant la identificació, lectura crítica i síntesi dels treballs de recerca clínica per produir la millor evidència disponible que permeti discriminar entre allò que pot ser beneficiós, el que pot ser perjudicial i a on es necessita més investigació.

Evidència fiable.

Decisions informades.

Millor salut.

Grups de revisió Cochrane més relacionats amb l'Obstetrícia i la Ginecologia



www.bibliotecacochrane.com



Evidencia fiable.
Decisiones informadas.
Mejor salud.

Español

Cochrane.org

Acceder

Título Resumen Palabra clave



Buscar por tema

Búsqueda avanzada

Revisiones Cochrane

Ensayos

Respuestas Clínicas Cochrane

Sobre nosotros

Ayuda

Sam Edwards/Gettyimages



**Reanimación con líquidos en pacientes críticos:
Coloides versus cristaloides**
Lee la revisión

Voisin/Phanie/SciencePhotoLibrary



**Prevención de las caídas en las
personas de edad avanzada**
Lee la colección especial

GARO/PHANIE/SciencePhotoLibrary



**¿Puede el Omega-3 prevenir
enfermedades cardiovasculares?**
Lee la revisión

Filtrar los resultados

Fecha ?

Fecha de publicación

Últimos tres meses 1

Últimos seis meses 2

Últimos nueve meses 2

Último año 2

Últimos dos años 5

Intervalo personalizado:

a

Aplicar

Borrar

Estado ?

Con cambios en las conclusiones 1

Revisiones Cochrane
51

Protocolos Cochrane
6

Ensayos
2985

Editoriales
2

Colecciones especiales
0

Languages: **Español** ✕

28 Revisiones Cochrane contienen 'cervical cancer en Título Resumen Palabra clave'

Cochrane **Base de Datos de Revisiones Sistemáticas**

Número 11 de 12, noviembre 2018

Seleccionar todo (28) Exportar referencia/s seleccionada/s [Mostrar todas las vistas previas](#)

Ordenar por ▼

1 **Cirugía para la neoplasia intraepitelial cervical**
Pierre PL Martin-Hirsch, Evangelos Paraskevaidis, Andrew Bryant, Heather O Dickinson

[Mostrar vista previa](#) ▼ Intervención Revisión 4 diciembre 2013 Acceso gratuito

2 **Dispositivos de recolección de muestras citológicas cervicales**

Pierre PL Martin-Hirsch, Gerry G Jarvis, Henry C Kitchener, Richard Lilford

[Mostrar vista previa](#) ▼ Intervención Revisión 24 julio 2000

3 **Retinoides para prevenir la progresión de la neoplasia intraepitelial cervical**

C. William Helm, Douglas J Lorenz, Nicholas J Meyer, William WB Pising, Judith L Wulff

Cochrane **Base de Datos de Revisiones Sistemáticas**

Histerectomía radical tipo II o tipo III en comparación con la quimiorradioterapia como intervención primaria para el cáncer de cuello uterino en estadio IB2

Revisión sistemática Cochrane - Intervención | Versión publicada: 12 octubre 2018



[Ver información sobre el artículo](#)

✉ [Vivek Nama](#) | [Georgios Angelopoulos](#) | [Jeremy Twigg](#) | [John B Murdoch](#) | [Jo Bailey](#) | [Theresa A Lawrie](#)

[Ver las declaraciones de intereses de los autores](#)

Resumen *disponible en* [English](#) | [Español](#) | [Français](#)

Antecedentes

El cáncer de cuello uterino es el cuarto cáncer más común en las mujeres, con 528 000 casos nuevos calculados a nivel global en 2012. Una gran mayoría (alrededor del 85%) de la carga de la enfermedad ocurre en los países de ingresos bajos y medios (PIBM),

Research targeting

Cochrane Review Groups were asked if they were aware of any reviews first published by their group between 2007 and 2011 that had generated subsequent research (e.g. contributed to successful grant applications for future primary research). Of the 13 groups that responded to this question, 12 (92%) said




FIGURE 2 New and updated reviews published by each CRG between 2007 and 2011. BJM, Bone, Joint and Muscle trauma; DAN, Depression, Anxiety and Neurosis; ENT, Ear, Nose and Throat; PaPaS, Pain, Palliative and Supportive Care. This figure has been reproduced from figure 2 © Bunn *et al.* The impact of Cochrane Systematic Reviews: a mixed method evaluation of outputs from Cochrane Review Groups supported by the UK National Institute for Health Research *Syst Rev* 2014;3:125,³⁸ under Creative Commons Licence 4.0, <https://creativecommons.org/licenses/by/4.0/>.

MOST ACCESSED COCHRANE MATERIALS IN 2017

A. FIVE MOST FREQUENTLY DOWNLOADED REVIEWS:

1. Support for healthy breastfeeding mothers with healthy term babies
4. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth

B. Most popular Cochrane PODCASTS:

1. Early additional food and fluids for healthy breastfed full-term infants
2. Support for breastfeeding mothers
4. Apoyo para la lactancia materna en madres e hijos sanos

Estratègia de Transferència del Coneixement



Knowledge translation

[Home](#) > [Review production](#) > Knowledge translation

Producing a Cochrane Review takes a lot of hard work. Use these resources to make sure that evidence is disseminated to the audiences that need it most – stakeholders, partners, clinicians, policy makers, and the public.

Comms Network



KT Working Groups



Framework and implementation plan



Consumers and the public

Those seeking health care, their families and carers, and the public



Practitioners

of health care including clinicians and public health practitioners



Policy-makers & healthcare managers

making decisions about health policy within all levels of management



Researchers & Research Funders

who need information regarding important gaps in the evidence

TABLE 4 Summary of information relating to inclusion of reviews in guidelines (stratified by CRG)

CRG	Total number of citations	Number of reviews cited in guidelines/ guidance	Total number of guidelines	Level of guideline		
				International	National	Local
Airways	54	45	16	3	13	0
BJM	18	12	9	0	8	1
Cystic Fibrosis and Genetic Disorders	16	15	13	3	9	1
DAN	84	52	26	10	16	0
Dementia and Cognitive Improvement	14	14	5	1	4	0
ENT	33	21	17	3	14	0
Epilepsy	8	7	3	1	2	0
Eyes and Vision	8	6	6	0	3	3
Gynaecological Cancer	7	7	3	0	3	0
Heart	37	19	26	5	21	0
Incontinence	29	22	9	1	8	0
Injuries	42	29	18	8	10	0
Neuromuscular	8	6	7	5	2	0
Oral Health	47	17	25	1	20	4
PaPaS	48	33	20	4	15	1
Pregnancy and Childbirth	129	85	33	15	18	0
Schizophrenia	57	43	8	2	6	0
Skin	20	14	14	3	11	0

TABLE 6 Details of Cochrane Reviews used to develop Cochrane quality and productivity topics

Review title	CRG	Year of Cochrane Review used	Potential savings	Other potential impacts
Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults	Airways	2009	Real cash savings	Increase in patient safety in children
Inhaled corticosteroids for cystic fibrosis	Cystic Fibrosis and Genetic Disorders	2009	Cash savings through reduced expenditure on drug budgets and fewer adverse events	Better outcome for patients by avoiding side effects of inhaled corticosteroids
Statins for the treatment of dementia	Dementia and Cognitive Improvement	2010	Cash releasing, although may be limited as patients may continue to take statins for other reasons	
Antigen-specific active immunotherapy for ovarian cancer	Gynaecological Cancer	2010	Mixture of cash savings and improved productivity	Improved clinical quality due to reduction in use of unproven therapies Improved patient safety due to decreased risk of adverse events
High-dose rate versus low-dose rate intracavity brachytherapy for locally advanced uterine cervix cancer	Gynaecological Cancer	2010	Cash savings	Improved clinical quality, better outcomes for patients
Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer	Gynaecological Cancer	2010	Cash savings	Improved clinical quality due to reduction in use of unproven therapies Improved patient safety due to decreased risk of adverse events
Antenatal interventions for fetomaternal alloimmune thrombocytopenia	Pregnancy and Childbirth	2011	Real cash savings	Improved clinical quality due to reduction in use of unproven therapies
Enemas during labour	Pregnancy and Childbirth	2007	Cash releasing	Improved patient and carer experience
Fetal and umbilical Doppler ultrasound in normal pregnancy	Pregnancy and Childbirth	2010	Cash releasing	Improved patient and carer experience
Intra-amniotic surfactant for women at risk of preterm birth for preventing respiratory distress in newborns	Pregnancy and Childbirth	2010	Real cash savings and improved productivity	Improved clinical quality due to reduction in use of unproven therapies and unnecessary procedures
Repeat digital cervical assessment in pregnancy for identifying women at risk of preterm labour	Pregnancy and Childbirth	2010	Minimal impact on cash but improved productivity	Improved clinical quality, patient safety and patient experience
Restricting oral fluid and food intake during labour	Pregnancy and Childbirth	2010	No impact on cash	Improved clinical quality and patient experience by reducing unnecessary

Col.laboració SCOG-Cochrane

- Acord marc
 - Projectes de revisió:
 - Després d'una histerectomia per via vaginal, amb o sense plàsties vaginals, està indicat l'ús del taponament vaginal durant 24 hores?
 - Després d'una cirurgia vaginal, quin és el millor moment per a retirar la sonda vesical?
 - Activitats de formació
 - Projectes de recerca
 - Activitats de transferència del coneixement

Cullera de plata per l'Obstetrícia ! (i la Ginecologia)





Societat Catalana
**d'Obstetrícia
i Ginecologia**



Congrés Català **d'Obstetrícia i Ginecologia**

7, 8 i 9 de novembre de 2018

Auditori AXA
BARCELONA



xbonfill@santpau.cat